Open-label, Uncontrolled, Prospective Long-term Observation of Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years
Phase of Trial: Phase IV
Latest Information Update: 24 Jul 2018
Price : $35 *
At a glance
- Drugs Iloprost (Primary)
- Indications Pulmonary arterial hypertension; Pulmonary hypertension
- Focus Adverse reactions; Therapeutic Use
- Acronyms OPTION
- Sponsors Bayer
- 16 Jul 2018 Status changed from active, no longer recruiting to completed.
- 11 Jun 2018 Planned End Date changed from 31 May 2018 to 18 Jun 2018.
- 10 Apr 2018 Planned End Date changed from 30 Mar 2018 to 31 May 2018.